A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears.
Adenoviruses offer great potential as gene therapy agents but are limited by the strong inflammatory response that occurs in response to the recombinant virus. Since the degree of inflammation correlates in part with the potential of the viral vector for replication, we constructed a preterminal protein (pTP) deletion mutant adenovirus type 5 vector, Ad5dl308DeltapTPbeta-gal, that is replication incompetent due to deletion of the pTP gene and that has the E1 genes replaced by the Escherichia coli lacZ reporter gene under the control of the cytomegalovirus major immediate-early promoter. This virus was compared with a first-generation, replication-defective adenovirus vector, Ad5dl308beta-gal, that is isogenic except that it contains a wild-type pTP gene. To examine transduction efficiency and induction of inflammation, we developed a novel system involving intradermal injection of BALB/c mouse ears. Mouse ears can be accurately measured to determine the degree of edema as an indirect measurement of inflammation. Edema and inflammation were induced in a dose- and time-dependent manner by both viruses and correlated well. LacZ activity correlated inversely with edema and inflammation. The pTP-defective vector Ad5dl308DeltapTPbeta-gal transduced mouse ears much more efficiently and induced edema and inflammatory cell infiltration approximately 10-fold less efficiently than the first-generation vector Ad5dl308beta-gal. The diminished inflammatory response and increased efficiency of transduction observed with Ad5dl308DeltapTPbeta-gal indicate its promise as a gene therapy agent for other tissues. The results also demonstrate that the mouse ear model offers potential for the study of adenovirus-induced inflammation because of the ready access of the ears, the relative ease of continuous measurement, and the sensitivity to adenovirus transducing vectors.
Moorhead
J W
JW
Department of Clinical Immunology, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Clayton
G H
GH
Smith
R L
RL
Schaack
J
J
D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D000818:Animals; D002461:Cell Line, Transformed; D002472:Cell Transformation, Viral; D003673:Defective Viruses / Q000235:genetics / Q000502:physiology; D004423:Ear / Q000821:virology; D005260:Female; D017353:Gene Deletion; D015870:Gene Expression; D017930:Genes, Reporter; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology / Q000502:physiology; D006801:Humans; D007271:Injections, Intradermal; D051379:Mice; D008807:Mice, Inbred BALB C; D008954:Models, Biological; D010750:Phosphoproteins / Q000235:genetics* / Q000276:immunology; D011498:Protein Precursors / Q000235:genetics* / Q000276:immunology; D014170:Transformation, Genetic; D014764:Viral Proteins / Q000235:genetics* / Q000276:immunology; D014779:Virus Replication; D001616:beta-Galactosidase / Q000235:genetics
D010750:Phosphoproteins; D011498:Protein Precursors; D014764:Viral Proteins; C085476:pTP protein, adenovirus; D001616:beta-Galactosidase